ClinicalTrials.gg

Program

efitazanamivir alfa

A development code. Also written as “CD388 Injection”, “MK-1406” and “MK-1406 Injection”.

In Merck's pipeline, MK-1406 is an investigational drug-Fc conjugate that consists of a neuraminidase inhibitor linked to an Fc fragment of a human antibody.. Its studies are mostly in Influenza, Human, led by Merck.

Furthest: phase 3, since Aug 29, 20258 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck84 open or runningphase 3since Aug 29, 2025Mar 8, 2022Dec 31, 2026phase 1 · NCT07300085
  • Named in Merck’s own pipeline as efitazanamivir alfa (MK-1406), phase 3, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Johnson & Johnson.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2022First study: phase 1 study in HealthyFirst studyNCT05285137 · 77 enrolled · United States
  2. Aug 29, 2022Phase 2 study in Influenza, HumanNCT05523089 · 59 enrolled · United Kingdom
  3. Nov 9, 2022Phase 1 study in HealthyNCT05619536 · 28 enrolled · United States
  4. Sep 20, 2024Phase 2 study in Influenza, HumanNCT06609460 · 5,071 enrolled · United States, United Kingdom
  5. Aug 29, 2025Phase 3 study in Influenza, HumanNCT07159763 · 10,000 planned · United States, Argentina, Australia and more
  6. Nov 6, 2025Phase 2 study in Influenza, HumanNCT07225959 · 400 enrolled · United States, United Kingdom
  7. Dec 10, 2025Phase 1 study in Influenza, HumanNCT07300085 · 710 planned · United States
  8. Jul 29, 2026Phase 1 study in HealthyNCT07743151 · 400 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Influenza, HumanNCT07300085
  2. Feb 5, 2027Primary completion: phase 1 study in HealthyNCT07743151
  3. Jul 2, 2027Primary completion: phase 3 study in Influenza, HumanNCT07159763
  4. Jul 31, 2027Primary completion: phase 2 study in Influenza, HumanNCT07225959

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“MK-1406 is an investigational drug-Fc conjugate that consists of a neuraminidase inhibitor linked to an Fc fragment of a human antibody.”the company's pipeline, read by Claude · source

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07743151Healthy · United States1RecruitingFeb 5, 2027400
NCT07300085Influenza, Human · United States1RecruitingDec 31, 2026710
NCT07225959Influenza, Human · United States, United Kingdom2Active, not recruitingJul 31, 2027400
NCT07159763Influenza, Human · United States, Argentina, Australia and more3RecruitingJul 2, 202710,000
NCT06609460Influenza, Human · United States, United Kingdom2CompletedOct 9, 20255,071
NCT05619536Healthy · United States1CompletedJul 14, 202328
NCT05523089Influenza, Human · United Kingdom2CompletedJul 17, 202359
NCT05285137Healthy · United States1CompletedOct 27, 202377

How it is read

Names in the registry

  • “CD388 Injection”, 3 entries
  • “MK-1406”, 2 entries
  • “MK-1406 Injection”, 2 entries
  • “CD388”, 1 entry

Codes read as this program: MK1406.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.